Catalyst
Slingshot members are tracking this event:
PharmaMar (PHM.MC) Phase 2 Data Evaluating PM1183 (lurbinectedin) in BRCA 1/2 -Associated Metastatic Breast Cancer Presented at the European Society of Medical Oncology (ESMO) Congress
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| PHM.MC |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 10, 2016
Related Projects
- A conversation with PharmaMar's Director of Oncology, Newly Hired COO, and Director of Capital Markets to discuss the upcoming pivotal year for the firm. PHM.MC, CLVS, TSRO Executed On: Mar 09, 2017 at 11:00 AM EST
Related Keywords
Phase 2, Pm1183, Lurbinectedin, Brca 1/2-, Metastatic Breast Cancer, European Society For Medical Oncology, Esmo 2016 Congress
